Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy

Trial Profile

Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Aug 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Cerebral palsy; Muscle spasticity
  • Focus Registrational; Therapeutic Use
  • Acronyms XARA
  • Sponsors Merz Pharmaceuticals GmbH
  • Most Recent Events

    • 18 Aug 2017 Planned End Date changed from 1 Jan 2019 to 1 Sep 2018.
    • 21 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 30 Sep 2016 Planned End Date changed from 1 Aug 2019 to 1 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top